[1]
|
Espert, R., Gadea, M., Alino, M., et al. (2018) Moyamoya Disease: Clinical, Neuroradiological, Neuropsychological and Genetic Perspective. Revue Neurologique, 66, S57-S64.
|
[2]
|
孙宁, 马骁, 魏中南, 等. 儿童烟雾病的治疗进展[J]. 中国现代医药杂志, 2021, 23(6): 105-108.
|
[3]
|
Hu, J., Luo, J. and Chen, Q. (2017) The Susceptibility Pathogenesis of Moyamoya Disease. World Neurosurgery, 101, 731-741. https://doi.org/10.1016/j.wneu.2017.01.083
|
[4]
|
Kuroda, S. and Houkin, K. (2008) Moyamoya Disease: Current Concepts and Future Perspectives. The Lancet Neurology, 7, 1056-1066. https://doi.org/10.1016/S1474-4422(08)70240-0
|
[5]
|
Torazawa, S., Miyawaki, S., Shinya, Y., et al. (2020) De Novo Development of Moyamoya Disease after Stereotactic Radiosurgery for Brain Arteriovenous Malfor-mation in a Patient with RNF213 p.Arg4810Lys (rs112735431). World Neurosurgery, 140, 276-282. https://doi.org/10.1016/j.wneu.2020.05.068
|
[6]
|
Shang, S., Zhou, D., Ya, J., et al. (2020) Progress in Moyamoya Disease. Neurosurgical Review, 43, 371-382.
https://doi.org/10.1007/s10143-018-0994-5
|
[7]
|
Tan, C., Niu, H., Duan, R., et al. (2019) Abnormal Embryonic Development of Cerebral Arteries as a Potential Cause of Moyamoya Disease. World Neurosurgery, 129, e224-e232. https://doi.org/10.1016/j.wneu.2019.05.116
|
[8]
|
Bersano, A., Guey, S., Bedini, G., et al. (2016) Research Pro-gresses in Understanding the Pathophysiology of Moyamoya Disease. Cerebrovascular Diseases, 41, 105-118. https://doi.org/10.1159/000442298
|
[9]
|
Kang, H.S., Kim, J.H., Phi, J.H., et al. (2010) Plasma Matrix Metallopro-teinases, Cytokines and Angiogenic Factors in Moyamoya Disease. Journal of Neurology, Neurosurgery and Psychiatry, 81, 673-678.
https://doi.org/10.1136/jnnp.2009.191817
|
[10]
|
Sakamoto, S., Kiura, Y., Yamasaki, F., et al. (2008) Expression of Vascular Endothelial Growth Factor in Dura Mater of Patients with Moyamoya Disease. Neurosurgical Review, 31, 77-81. https://doi.org/10.1007/s10143-007-0102-8
|
[11]
|
Jeon, J.S., Ahn, J.H., Moon, Y.J., et al. (2014) Expression of Cellular Retinoic Acid-Binding Protein-I (CRABP-I) in the Cerebrospinal Fluid of Adult Onset Moyamoya Disease and Its Association with Clinical Presentation and Postoperative Haemodynamic Change. Journal of Neurology, Neuro-surgery and Psychiatry, 85, 726-731.
https://doi.org/10.1136/jnnp-2013-305953
|
[12]
|
Nanba, R., Kuroda, S., Ishikawa, T., et al. (2004) Increased Ex-pression of Hepatocyte Growth Factor in Cerebrospinal Fluid and Intracranial Artery in Moyamoya Disease. Stroke, 35, 2837- 2842.
https://doi.org/10.1161/01.STR.0000148237.13659.e6
|
[13]
|
Han, Z., Li, L., Liu, P., et al. (2020) Metabolic Ad-justments by LncRNAs in Peripheral Neutrophils Partly Account for the Complete Compensation of Asymptomatic MMD Patients. CNS & Neurological Disorders—Drug Targets, 19, 306-317.
https://doi.org/10.2174/1871527319666200618150827
|
[14]
|
Yamamoto, M., Aoyagi, M., Tajima, S., et al. (1997) Increase in Elastin Gene Expression and Protein Synthesis in Arterial Smooth Muscle Cells Derived from Patients with Moyamoya Disease. Stroke, 28, 1733-1738.
https://doi.org/10.1161/01.STR.28.9.1733
|
[15]
|
Bedini, G., Blecharz, K.G., Nava, S., et al. (2016) Vasculogenic and Angiogenic Pathways in Moyamoya Disease. Current Medicinal Chemistry, 23, 315-345. https://doi.org/10.2174/092986732304160204181543
|
[16]
|
Weinberg, D.G., Arnaout, O.M., Rahme, R.J., et al. (2011) Moyamoya Disease: A Review of Histopathology, Biochemistry, and Genetics. Neurosurgical Focus, 30, E20.
|
[17]
|
Yamashita, M., Oka, K. and Tanaka, K. (1984) Cervico-Cephalic Arterial Thrombi and Thromboemboli in Moyamoya Disease—Possible Correlation with Progressive Intimal Thickening in the Intracranial Major Arteries. Stroke, 15, 264-270.
https://doi.org/10.1161/01.STR.15.2.264
|
[18]
|
Houkin, K., Yoshimoto, T., Abe, H., et al. (1998) Role of Basic Fi-broblast Growth Factor in the Pathogenesis of Moyamoya Disease. Neurosurgical Focus, 5, e2.
|
[19]
|
Huang, S., Guo, Z.N., Shi, M., et al. (2017) Etiology and Pathogenesis of Moyamoya Disease: An Update on Disease Prevalence. Inter-national Journal of Stroke, 12, 246-253. https://doi.org/10.1177/1747493017694393
|
[20]
|
Parray, T., Martin, T.W. and Siddiqui, S. (2011) Moyamoya Disease: A Review of the Disease and Anesthetic Management. Journal of Neuro-surgical Anesthesiology, 23, 100-109. https://doi.org/10.1097/ANA.0b013e3181f84fac
|
[21]
|
Hojo, M., Hoshimaru, M., Miyamoto, S., et al. (1998) Role of Transforming Growth Factor-beta1 in the Pathogenesis of Moyamoya Disease. Journal of Neurosurgery, 89, 623-629. https://doi.org/10.3171/jns.1998.89.4.0623
|
[22]
|
Han, W., Jin, F., Zhang, H., et al. (2020) Association of Brain-Gut Peptides with Inflammatory Cytokines in Moyamoya Disease. Mediators of Inflammation, 2020, Article ID: 5847478. https://doi.org/10.1155/2020/5847478
|
[23]
|
Yamamoto, M., Aoyagi, M., Fukai, N., et al. (1999) Increase in Prostaglandin E(2) Production by Interleukin-1beta in Arterial Smooth Muscle Cells Derived from Patients with Moyamoya Disease. Circulation Research, 85, 912-918.
https://doi.org/10.1161/01.RES.85.10.912
|
[24]
|
Bamforth, S.D., Lightman, S.L. and Greenwood, J. (1997) Inter-leukin-1 Beta-Induced Disruption of the Retinal Vascular Barrier of the Central Nervous System Is Mediated through Leukocyte Recruitment and Histamine. The American Journal of Pathology, 150, 329-340.
|
[25]
|
Shinkaruk, S., Bayle, M., Laïn, G., et al. (2003) Vascular Endothelial Cell Growth Factor (VEGF), an Emerging Target for Cancer Chemo-therapy. Current Medicinal Chemistry—Anti-Cancer Agents, 3, 95-117.
https://doi.org/10.2174/1568011033353452
|
[26]
|
He, J., Wang, R., Zhang, D., et al. (2014) Expression of Circulat-ing Vascular Endothelial Growth Factor-Antagonizing Cytokines and Vascular Stabilizing Factors Prior to and Following Bypass Surgery in Patients with Moyamoya Disease. Experimental and Therapeutic Medicine, 8, 302-308. https://doi.org/10.3892/etm.2014.1713
|
[27]
|
Rosenstein, J.M., Mani, N., Silverman, W.F., et al. (1998) Patterns of Brain Angiogenesis after Vascular Endothelial Growth Factor Administration in Vitro and in Vivo. Proceedings of the National Academy of Sciences of the United States of America, 95, 7086-7091. https://doi.org/10.1073/pnas.95.12.7086
|
[28]
|
Shima, D.T., Adamis, A.P., Ferrara, N., et al. (1995) Hypoxic Induc-tion of Endothelial Cell Growth Factors in Retinal Cells: Identification and Characterization of Vascular Endothelial Growth Factor (VEGF) as the Mitogen. Molecular Medicine, 1, 182-193. https://doi.org/10.1007/BF03401566
|
[29]
|
Cobbs, C.S., Chen, J., Greenberg, D.A., et al. (1998) Vascular Endothe-lial Growth Factor Expression in Transient Focal Cerebral Ischemia in the Rat. Neuroscience Letters, 249, 79-82. https://doi.org/10.1016/S0304-3940(98)00377-2
|
[30]
|
Blecharz-Lang, K.G., Prinz, V., Burek, M., et al. (2018) Ge-latinolytic Activity of Autocrine Matrix Metalloproteinase-9 Leads to Endothelial De-Arrangement in Moyamoya Disease. Journal of Cerebral Blood Flow & Metabolism, 38, 1940-1953. https://doi.org/10.1177/0271678X18768443
|
[31]
|
刘超. 转化生长因子B1单核苷酸多态性与烟雾病的相关性研究[D]: [博士学位论文]. 长春: 吉林大学, 2012.
|
[32]
|
苗军, 刘少云, 崔松, 等. 脑出血患者外周血及脑组织中IL-17、TGF-β的表达及意义[J]. 脑与神经疾病杂志, 2017, 25(7): 426-428.
|
[33]
|
陈捷, 程亚玲, 陈海燕, 等. 成年烟雾病患者血清血管细胞黏附分子1、基质金属蛋白酶9、转化生长因子β、血管内皮生长因子水平变化及其临床意义研究[J]. 实用心脑肺血管病杂志, 2020, 28(5): 27-33.
|
[34]
|
Ueno, M., Kira, R., Matsushima, T., et al. (2000) Moyamoya Disease and Transforming Growth Fac-tor-beta1. Journal of Neurosurgery, 92, 907-908.
|
[35]
|
Liu, C., Roder, C., Schulte, C., et al. (2012) Analysis of TGFB1 in European and Japanese Moyamoya Disease Patients. European Journal of Medical Genetics, 55, 531-534. https://doi.org/10.1016/j.ejmg.2012.05.002
|
[36]
|
Roder, C., Peters, V., Kasuya, H., et al. (2010) Polymorphisms in TGFB1 and PDGFRB Are Associated with Moyamoya Disease in European Patients. Acta Neurochirurgica (Wien), 152, 2153-2160.
https://doi.org/10.1007/s00701-010-0711-9
|